ArticleAnnals of hematology2026
Thrombosis in adult primary immune thrombocytopenia in Korea: incidence and risk factors in a 20-year retrospective cohort.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune thrombocytopenia (ITP) is primarily a bleeding disorder, yet thrombotic events occur and remain challenging to predict, particularly in Asian populations and across real-world treatment patterns. We evaluated thrombosis incidence and associated clinical and therapy-related factors in Korean adults with primary ITP.
methodsWe conducted a retrospective cohort study of adults (≥ 19 years) with hematologist-confirmed primary ITP at Seoul National University Bundang Hospital from April 1, 2003 to December 31, 2023. Thrombotic events were identified by diagnostic codes and confirmed by review of imaging and clinical documentation. Patients were classified into five ever-treated groups: never treated (Group 1), first-line only (Group 2), immunosuppressive agents without TPO-RA (Group 3), TPO-RA monotherapy (Group 4), and TPO-RA combination therapy (Group 5). Incidence rates were calculated per 100 person-years (PY). Predictors were assessed using Firth's penalized logistic regression.
resultsAmong 1,038 patients (median age 57 years; 42.6% male), median follow-up was 1.4 years (IQR, 0.3-4.5) with 3,185 PY. Fourteen patients experienced thrombotic events (19 total; 4 arterial, 15 venous), yielding an incidence of 0.44 per 100 PY (95% CI, 0.24-0.74). No events occurred in never-treated patients; events occurred only in Groups 2-5 (p < 0.001). In multivariable analysis, atrial fibrillation (OR 6.01), splenectomy (OR 6.97), and higher ordinal treatment-intensity group (OR 2.16 per step) were independently associated with thrombosis (all p ≤ 0.027).
conclusionThrombosis was uncommon overall but clustered in high-risk contexts-atrial fibrillation, post-splenectomy status, and higher treatment-intensity patterns, particularly TPO-RA-based regimens. The association between treatment intensity and thrombosis most likely reflects a higher-risk clinical context-including refractory disease, greater inflammatory burden, and more intensive clinical surveillance-rather than a direct causal effect of therapy. These findings support individualized risk assessment, integrating comorbidity profiles and treatment trajectories during periods of therapy escalation and platelet instability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.